CTLA4 and neoplasm: As mentioned above, PAD4 inhibitors are able to inhibit the expression of genes, such as PD1 and LAG3, which are potential immune checkpoint inhibitors, and their ability to inhibit tumor progression can be enhanced in combination with anti-CTLA-4 and anti-PD-1 antibodies.